为您找到相关结果约500个

你是不是要搜索 期刊SCI-Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) 点击跳转

Antiplatelet Efficacy of 75 mg Aspirin Once a Day versus Twice a Day Dosing in Type 2 Diabetes MellitusPatients-A Longitudinal Open Label Study

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Efficacy and safety of once daily liraglutide versus twice daily exenatide in type 2 diabetic patients

Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasonein patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatidetwice daily in patients with type 2 diabetes

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase3 trial

The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function inType 2 Diabetes: A Systematic Review and Network Meta-Analysis

Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial

A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in PatientsWith Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin

Comparison of the Effectiveness of Once-Daily Alogliptin/Metformin and Twice-Daily Anagliptin/MetforminCombination Tablet in a Randomized, Parallel-Group, Open-Label Trial in Japanese Patients with Type2 Diabetes

Once-Daily versus Twice-Daily Tacrolimus in Living Kidney Transplantation: A Multicenter, Parallel Group, Open-Label, 5-Year, Randomized Non-Inferiority Trial

The diabetes community exercise programme plus usual care versus usual care in patients with type 2 diabetes: A randomised, two-arm, parallel, open-label trial

为您找到相关结果约500个

共500条页码: 1/34页15条/页